Budget 2023Budget 2023


  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
Budget 2023
Budget 2023
you are here: HomeNewsTrendsHealth

Ray of hope for blood cancer, lymphoma patients as CAR-T cell therapy to be available in India

ImmunoACT, an Indian Institute of Technology- Bombay spin-off, says it is working to make the therapy available for specific types of cancer at a fraction of what it costs in countries like the US

June 12, 2022 / 12:17 PM IST
Representational image

Representational image

The first CAR-T cell therapy, a type of gene therapy, to treat cancers of blood and lymphatic system is likely to be available in India from 2023, offering hope to patients who can’t afford to travel abroad for the expensive treatment.

On June 11, ImmunoACT, an Indian Institute of Technology, Bombay spin-off company, launched its facility to start production on a large scale. As of now, CAR-T cell therapy is not available in India, Patients have to travel to countries like the US and it costs nearly Rs 3-4 crore.

The indigenously developed CAR-T cell therapy was the result of intense research over the last eight years and had now been patented, Rahul Purwar, a senior IIT-Bombay faculty who is also the founder and CEO of ImmunoACT, said.

Incubated at the Society of Innovation and Entrepreneurship at IIT-B, ImmunoACT now has Hyderabad-based pharmaceutical major Laurus Labs as a partner and is looking to make the treatment available at Rs 20-30 lakh a patient in India, the company said.